Blueprint Medicines Corp · Q2 2024 earnings

Briefing

Blueprint Medicines reported strong second-quarter results, highlighted by AYVAKIT net product revenues, and raised full-year revenue guidance.

Blueprint Medicines reported a strong second quarter, achieving $114.1 million in AYVAKIT net product revenues and raising the full-year revenue guidance to $435 million to $450 million. The company is progressing with its pipeline, including the initiation of a Phase 1 trial for BLU-808 and plans for a registration-enabling study of elenestinib.

• Achieved $114.1 million in AYVAKIT net product revenues in Q2 2024.
• Raised AYVAKIT net product revenue guidance to $435 million to $450 million for 2024.
• Initiated Phase 1 healthy volunteer trial of wild-type KIT inhibitor BLU-808.
• Expect to initiate the registration-enabling HARBOR Part 2 study of elenestinib in indolent systemic mastocytosis later this year.

Headline financials

Revenue & EPS history

Blueprint Medicines anticipates approximately $435 million to $450 million in global AYVAKIT net product revenues for all approved indications in 2024. The company continues to expect that full-year operating expenses and cash burn will decline in 2024 as compared to 2023, and that its existing cash, cash equivalents and investments, together with anticipated product revenues, will enable the company to maintain a durable capital position to achieve a self-sustainable financial profile.